P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

• J.-J. Kiladjian,
• A. Tefferi,
• F. Passamonti,
• A. Vannucchi,
• M. Talpaz,
• F. Cervantes,
• C. N. Harrison,
• R. A. Mesa,
• J. Mascarenhas,
• N. Schaap,
• S. Verstovsek,
• T. Devos,
• S. Rose,
• J. Zhang,
• O. Sy,
• A. Pardanani

Affiliations

J.-J. Kiladjian

1 Hôpital Saint-Louis; Université de Paris, INSERM, Paris, France

A. Tefferi

2 Mayo Clinic of Rochester, Rochester, United States of America

F. Passamonti

3 University of Insubria, Varese

A. Vannucchi

4 CRIMM, University of Florence, AOU Careggi, Florence, Italy

M. Talpaz

5 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States of America

F. Cervantes

6 Hospital Clinic Provincial de Barcelona, Barcelona, Spain

C. N. Harrison

7 Guy’s and St Thomas’ Hospital, London, United Kingdom

R. A. Mesa

8 Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio

J. Mascarenhas

9 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States of America

N. Schaap

10 Radboud University Medical Centre, Nijmegen, Netherlands

S. Verstovsek

11 The University of Texas MD Anderson Cancer Center, Houston, United States of America

T. Devos

12 University Hospitals Leuven and Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium

S. Rose

13 Bristol Myers Squibb, Princeton, United States of America

J. Zhang

13 Bristol Myers Squibb, Princeton, United States of America

O. Sy

13 Bristol Myers Squibb, Princeton, United States of America

A. Pardanani

2 Mayo Clinic of Rochester, Rochester, United States of America